Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role

Stefania De Lorenzo(Medica (Italy)), Francesco Tovoli(Azienda USL di Bologna), Alessandro Mazzotta(Inserm), Francesco Vasuri(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Julien Edeline(Centre Eugène Marquis), Deborah Malvi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Karim Boudjéma(Inserm), Matteo Renzulli(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Heithem Jeddou(Inserm), Antonietta D’Errico(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Bruno Turlin(Inserm), Matteo Cescon(University of Bologna), Thomas Uguen(Centre Hospitalier Universitaire de Rennes), Alessandro Granito(Azienda USL di Bologna), Astrid Lièvre(Inserm), Giovanni Brandi(Medica (Italy))
Cancers
October 29, 2020
Cited by 55Open Access
Full Text

Abstract

Non-alcoholic fatty liver disease (NAFLD) and its most aggressive form, non-alcoholic steatohepatitis (NASH), are causing a rise in the prevalence of hepatocellular carcinoma. Data about NAFLD/NASH and intrahepatic cholangiocarcinoma (iCCA) are few and contradictory, coming from population registries that do not correctly distinguish between NAFLD and NASH. We evaluated the prevalence of NAFLD and NASH in peritumoral tissue of resected iCCA (n = 180) and in needle biopsies of matched liver donors. Data of iCCA patients were subsequently analysed to compare NASH-related iCCA (Group A), iCCA arisen in a healthy liver (Group B) or in patients with classical iCCA risk factors (Group C). NASH was found in 22.5% of 129 iCCA patients without known risk factors and in 6.2% of matched controls (risk ratio 3.625, 95% confidence interval 1.723–7.626, p < 0.001), while NAFLD was equally represented in both groups. The overall survival of NASH-related iCCA was inferior to that of patients with healthy liver (38.5 vs. 48.1 months, p = 0.003) and similar to that of patients with known risk factors (31.9 months, p = 0.948), regardless of liver fibrosis. The multivariable Cox regression confirmed NASH as a prognostic factor (hazard ratio 1.773, 95% confidence interval 1.156–2.718, p = 0.009). We concluded that NASH (but not NAFLD) is a risk factor for iCCA and might affect its prognosis. Dissecting NASH from NAFLD by histology is necessary to correctly assess the actual role of these conditions. Prevention protocols for NASH patients should also consider the risk for iCCA and not only HCC. Mechanistic studies aimed to find a direct pathogenic link between NASH and iCCA could add further relevant information.


Related Papers

No related papers found

Powered by citation graph analysis